Article metrics
PDF
Other content recommended for you
- Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
- Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects
- Increased IP-10 production by blood–nerve barrier in multifocal acquired demyelinating sensory and motor neuropathy and multifocal motor neuropathy
- Electrodiagnostic data-driven clustering identifies a prognostically different subgroup of patients with chronic inflammatory demyelinating polyneuropathy
- Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy
- Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy
- Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies
- Multifocal motor neuropathy: controversies and priorities
- Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review
- Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial